SCHEMBL6284582

SCHEMBL6284582

Clc1ccc(-c2nc3cc(OCC4CO4)ccc3o2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CETP P11597 5/20 0.51
UTRN P46939 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 3/20 0.49
HPGD P15428 3/20 0.49
LMNA P02545 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
CASP3 P42574 2/20 0.48
SENP7 Q9BQF6 2/20 0.48
SENP6 Q9GZR1 2/20 0.48
MAPT P10636 7/20 0.46
HSD17B10 Q99714 2/20 0.46
TSHR P16473 1/20 0.46
KDR P35968 1/20 0.45
SENP8 Q96LD8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5227432 0.88 ACSL1 (0.53) SMN1; SMN2KDM4EALDH1A1HPGDNPC1
SCHEMBL5995331 0.88 ACSL1 (0.53) SMN1; SMN2KDM4EALDH1A1HPGDNPC1
SCHEMBL6448244 0.86 HDAC6 (0.52) CETPHSD17B10TSHR
SCHEMBL4041183 0.85 ESR1 (0.46) CETPSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL5230999 0.85 UTRN (0.52) CETPUTRNSMN1; SMN2ALDH1A1HPGD
SCHEMBL17929619 0.85 MAPT (0.47) CETPSMN1; SMN2KDM4EHPGDLMNA
SCHEMBL4041870 0.85 ESR1 (0.46) CETPSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17929618 0.85 MAPT (0.47) CETPSMN1; SMN2KDM4EHPGDLMNA
SCHEMBL17929621 0.85 RXFP1 (0.55) UTRNSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17929620 0.85 RXFP1 (0.55) UTRNSMN1; SMN2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849632-B2 Heteroaryl alkyl piperazine derivatives CV THERAPEUTICS, INC. (US) 2005-02-01 US disclosed
US-20040192702-A1 Heteroaryl alkyl piperazine derivatives ZABLOCKI JEFF (US) 2004-09-30 US disclosed
US-20030216409-A1 Heteroaryl alkyl piperazine derivatives CV THERAPEUTICS, INC. 2003-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192702-A1 Heteroaryl alkyl piperazine derivatives ATP2A1, CPT1B, ATP2A3 CETP 3376/4885UTRN 1904/4885SMN1; SMN2 1073/4885
US-20030216409-A1 Heteroaryl alkyl piperazine derivatives ATP2A1, CPT1B, ATP2A3 CETP 3376/4885UTRN 1904/4885SMN1; SMN2 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.